Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation

Pharmacological Reports

Volumn 62, Issue 6, 2010, Pages 1159-1169

  Turolo, Stefano ^a   Tirelli, Amedea S ^a   Ferraresso, Mariano ^b   Ghio, Luciana ^a   Belingheri, Mirco ^a   Groppali, Elena ^a   Torresani, Erminio ^a   Edefonti, Alberto ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

ABCB1 polymorphisms; Allele distribution; Calcineurin inhibitors; CYP3A4*1B; CYP3A5; Kidney transplantation

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

AFRICAN AMERICAN; ARTICLE; ASIAN; CAUCASIAN; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENETIC SCREENING; GENOTYPE; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PROTEIN FUNCTION; RACE DIFFERENCE; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79551502415     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70378-9     Document Type: Article

References (62)

1. 4. J Natl Cancer Inst, 1999, 91, 1588-1590.
2. Anglicheau D, Flamant M, Schlageter MH, Martinez F, Cassinat B, Beaune P, Legendre C, Thervet E: Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Neph Dial Transplant, 2003, 18, 2409-2414.
3. Anglicheau D, Le Corre D, Lechaton S, Laurant-Puig P, Kreis H, Beaune P, Legendre C, Thervet E: Consequences of genetic polymorphism for sirolimus requirement after renal transplant in patients on primary sirolimus therapy. Am J Transplant, 2005, 5, 595-603.
4. Anglicheau D, Legendre C, Thervert E: Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from retrospective analyses to prospetive studies. Transplant Proc, 2007, 39, 2142-2144.
5. Aoyama T, Korzekwa K, Nagata K, Adesnik M, Reiss A, Lapenson DP, Gillette J et al.: Sequence requirements for cytochrome P-450IIB1 catalytic activity. Alteration of the stereospecificity and regioselectivity of steroid hydroxylation by a simultaneous change of two hydrophobic amino acid residues to phenylalanine. J Biol Chem, 1989, 264, 21327-21333.
6. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI: Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol, 1994, 12, 835-842.
7. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E et al.: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther, 2001, 69, 169-174.
8. Cavaco I, Gil JP, Gil-Berglund E, Ribeiro V: Cyp3A4 and ABCB1 alleles in a Portuguese population. Clin Chem Lab Med, 2003, 41, 1345-1350.
9. Chelule PK, Gordon M, Palanee T, Page T, Mosam A, Coovadia HM, Cassol S: MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations in KwaZulu-Natal, South Africa. Clin Pharmacol Ther, 2003, 74, 195-196.
10. Choi JH, Lee YJ, Jang SB, Lee JE, Kim KH, Park K: Influence of the CYP3A5 and MDR1 genetic polymorphism on the pharmacokinetics of tacrolimus in healthy Korean subjects. Br J Clin Pharmacol, 2007, 64, 185-189.
11. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ: Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of ABCB1 haplotypes on cyclosporine dispositon in heart transplant recipients. Pharmacogenetics, 2003, 13, 89-95.
12. Crettol S, Déglon JJ, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I. Monnat M, Eap CB: ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther, 2006, 80, 668-681.
13. Crettol S, Venetz JP, Fontana M, Aubert JD, Pascual M, Eap CB: CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphism, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit, 2008, 30, 689-699.
14. Cummings BS, Parker JC, Lash LH.: Role of cytochrome P-450 and glutathione S-transferase α in metabolism and cytotoxicity of trichloroethylene in rat kidney. Biochem Pharmacol, 2000, 59, 531-539.
15. Estrela RC, Ribeiro FS, Carvalho RS, Gregório SP, Dias-Neto E, Struchiner CJ, Suarez-Kurtz G: Distribution of ABCB1 polymorphisms among Brazilians: impact of population admixture. Pharmacogenomics, 2008, 9, 267-276.
16. Fahr A: Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet, 1993, 24, 472-495.
17. Fanta S, Niemi M, Jönsson S, Karlsson MO, Holmberg C, Neuvonen PJ, Hoppu K, Backman JT: Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1polymorphisms. Pharmacogenet Genomics, 2008, 18, 77-90.
18. Ferraresso M, Ghio L, Zacchello G, Murer L, Ginevri F, Perfumo F, Zanon GF et al.: Pharmacokinetic of cyclosporine microemulsion in pediatric kidney recipients receiving A quadruple immunosuppressive regimen: the value of C2 blood levels. Transplantation, 2005, 79, 1164-1168.
19. Ferraresso M, Tirelli A, Ghio L, Grillo P, Martina V, Torresani E, Edefonti A: Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients. Pediatric Transplant, 2007, 11, 296-300.
20. Ferreira PE, Veiga MI, Cavaco I, Martins JP, Andersson B, Mushin S, Ali AS et al.: Polymorphism of antimalaria drug metabolizing, nuclear receptor, and drug transport genes among malaria patients in Zanzibar, East Africa. Ther Drug Monit, 2008, 30, 10-15.
21. Fredericks S, Jorga A, MacPhee IA, Reboux S, Shiferaw E, Moreton M, Carter ND et al.: Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements. Clin Transplant, 2007, 21, 252-257.
22. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmoller J, Frotchl R, Kopke K, Gerloff T et al.: Polymorphism of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol, 2003, 59, 303-312.
23. Gervasini G, Vizcanio S, Gaisba C, Carrillo JA, Benitez J: Differences in CYP3A5 genotype distribution and combination with other polymorphisms between Spaniards and other Caucasian populations. Ther Drug Monit, 2005, 27, 819-821.
24. Goreva OB, Grisitanova AY, Domnikova NP, Mukhin OV, Lyakhovich VV: MDR1 gene C1236T and C6+139T polymorphism in the Russian population: association to lymphoproliferative disease and drug resistance. Bull Exp Biol Med, 2004, 138, 404-406.
25. Haufroid V, Mourad M, van Kerckhove V, Wawrzyniak J, DeMeyer M, Eddour DC, Malaise J et al.: The effect of CYP3A5 and MDR1 (ABCB1) polymorphism on cyclosporine and tacrolimus dose requirement and trough blood levels in stable renal transplant patients. Pharmacogenetics, 2004, 14, 147-154.
26. Haufroid V, Wallemacq P, Van Kerckhove V, Elans L, De Meyer M, Eddour DC: CYP3A5 and ABCB1 polymorphism and tacrolimus pharmacokinetics in renal transplant candidates: guideline from an experimental study. Am J Transplant, 2006, 6, 2706-2713.
27. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T: Genetic polymorphism of the CYP3A4, CYP3A5, and MDR1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther, 2003, 74, 245-254.
28. Hilli J, Rane A, Lundgren S, Bertilsson L, Laine K: Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population. Fundam Clin Pharmacol, 2007, 21, 379-386.
29. Hoffmeyer S, Burk O, von Riechter O, Arnold HP, Borockmoller J, Johne A, Cascorbi I et al: Functional polymorphism of the human multidrug-resistence gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA, 2000, 97, 3473-3478.
30. Hu YF, Qiu W, Liu ZQ, Zhu LJ, Liu ZQ, Tu JH, Wang D et al.: Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Clin Exp Pharmacol Physiol, 2006, 33, 1093-1098.
31. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC et al.: The genetic determinats of the CYP3A5 polymorphism. Pharmacogenetics, 2001, 11, 773-779.
32. Ishikawa T, Hirano H, Onishi Y, Sakurai A, Tarui S: Functional evaluation of MDR1 (P-glycoprotein) polymorphisms: high speed screening and structure activity relationship analyses. Drug Metab Pharmacokinet, 2004, 19, 1-14.
33. Jonge H de, Naesens M., Kuypers DR: New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit, 2009, 3, 416-435.
34. Kerb R, Hoffmeyer S, Brinkmann U: ABC drug transporter: hereditary polymorphism and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics, 2001, 2, 51-64.
35. Kim R, Leake B, Choo E, Dresser G, Kubba S, Schwarz U, Taylor A et al.: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther, 2001, 70, 189-199. (Pubitemid 32777772)
36. Komar AA: Silent SNP: impact on gene function and phenotype. Pharmacogenomics, 2007, 8, 1075-1080.
37. Kronbach T, Fischer V, Meyer UA: Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther, 1988, 43, 630-635.
38. Kuehl P Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB et al:. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet, 2001, 27, 383-391
39. Kurzawski M, Pawlik A, Górnik W, Droździk M: Frequency of common MDR1 gene variants in a Polish population. Pharmacol Rep, 2006, 58, 35-40.
40. Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y: CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther, 2007, 82, 711-725.
41. Leonard GD, Fojo T, Bates TE: The role of ABC transporters in clinical practice. Oncologist, 2003, 8, 411-424.
42. Levran O, O'Hara K, Peles E, Li D, Barral S, Ray B, Borg L et al.: ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet, 2008, 17, 2219-2227.
43. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB et al.: Role of intestinal P-glycoprotein (MDR1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther, 1997, 62, 248-260.
44. MacPhee IA, Holt DW: A pharmacogenetic strategy for immunosuppressive based on the CYP3A5 genotype. Transplantation, 2008, 85, 163-165.
45. Manitpisitkul W, McCann E, Lee S, Weir MR. Drug interaction in transplant patients : what everyone should know. Curr Opin Nephrol Hypertens, 2009, 18, 404-411.
46. Montini G, Murer L, Ghio L, Pietrobon B, Ginevri F, Ferraresso M, Cardillo M et al.: One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient. Transpl Int, 2005, 18, 36-42.
47. Pechandova K, Buzkova H, Slanar O, Perlik F: Polymorphism of the MDR1 gene in the Czech Population. Folia Biol (Praha), 2006, 52, 184-189.
48. Press RR, Ploegger BA, dan Hartingh J, van der Streaten T, van Pelt J, Danhof M, de Fijiter JW, Guchelaar HJ: Explaining variability in tacrolimus pharmacokinetics to optimise early exposure in adult kidney transplant recipients. Ther Drug Monit, 2009, 31, 187-197.
49. Sakaeda T, Nakamura T, Okumura K: MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull, 2002, 25, 1391-1400.
50. Sakaeda T, Nakamura T, Okumura K: Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics, 2003, 4, 397-410.
51. Schiff J, Cole E, Cantarovich M: Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol, 2007, 2, 374-384.
52. Sonneveld P, Durie BG, Lokhorst HM, Marie JP, Solbu G, Suciu S, Zittoun R et al.: Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet, 1992, 340, 255-259.
53. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M: Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther, 1997, 61, 331-339.
54. Staatz CE, Tett SE: Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation . Clin Pharmacokinet, 2004, 43, 623-653.
55. Suarez-Kurtz G, Perini JA, Bastos-Rodrigues L, Pena SD, Struchiner C: Impact of population admixture on the distribution of the CYP3A5*3 polymorphism. Pharmacogenomics, 2007, 8, 1299-1306.
56. Van Gelder T, Klupp J, Sawamoto T, Christians U, Morris RE: ATP-binding cassette transporters and calcineurin inhibitors: potential clinical implications. Transplant Proc, 2001, 33, 2420-2421.
57. 2+, deoxynucleotide triphosphate and dimethyl sulfoxide concentrations with comparison to alternative empirical formulas. Clin Chem, 2001, 47, 1956-1961.
58. Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M, Honaker MR et al.: The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol, 2003, 43, 555-564.
59. Yokogawa K, Shimada T, Higashi Y, Itoh Y, Masue T, Ishizaki J, Asahi M, Miyamoto K: Modulation of MDR1a and CYP3A gene expression in the intestine and liver as possible cause of changes in the cyclosporin A disposition kinetics by dexamethasone. Biochem Pharmacol, 2002, 63, 777-783.
60. Wang D, Sadée W: Searching for polymorphisms that affect gene expression and mRNA processing: example MDR1 (ABCB1). The AAPS Journal, 2006, 8, E515-E520.
61. Wang J, Zeevi A, McCurry K, Schuetz E, Zheng H, Iacono A, McDade K et al.: Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors. Transpl Immunol, 2006, 15, 235-240.
62. Wielandt Na AM, Vollrath Ra V, Chianale BJ: Polimorfismos del gen de resistencia a múltiples drogas (MDR1) en poblaciones chilenas: mapuche, mestiza y maorí. Rev Méd Chile, 2004, 132, 1061-1068.